MACK - Merrimack Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-20.36M

Cash

244.1M

Avg Qtr Burn

-620K

Short % of Float

8.72%

Insider Ownership

1.19%

Institutional Own.

62.98%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Onivyde® (irinotecan liposome injection) + 5 fluorouracil/leucovorin+ oxaliplatin Details Cancer, Pancreatic cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onivyde® (irinotecan liposome injection) Details Cancer, Small cell lung cancer, Lung cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.